Altimmune (ALT) Return on Capital Employed (2011 - 2026)

Altimmune (ALT) has 16 years of Return on Capital Employed data on file, last reported at 32.69% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 3821.0% year-over-year to 32.69% in Q1 2026; TTM through Mar 2026 was 32.69%, a 3821.0% increase from a year earlier, with the FY2025 full-year figure at 48.55%, up 1417.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 32.69%, up from 40.35% in the prior quarter.
• Over the last five years, Return on Capital Employed for ALT reached as high as 32.69% in Q1 2026 and fell as low as 77.5% in Q4 2024.
• Historically, Return on Capital Employed has averaged 53.92% across 5 years, with a median of 52.37% in 2023.
• Across the five-year window, Return on Capital Employed tumbled 2712 bps in 2022 and jumped 3821 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 44.08% in 2022, then fell by 23 bps to 54.36% in 2023, then sank by 43 bps to 77.5% in 2024, then surged by 48 bps to 40.35% in 2025, then climbed by 19 bps to 32.69% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 32.69% in Q1 2026, 40.35% in Q4 2025, and 47.17% in Q3 2025.